SHANGHAI MEDICILON INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.01 CNY | -6.48% |
|
-8.75% | -60.50% |
| Sales 2024 * | 2.02B 279M 21.98B | Sales 2025 * | 2.42B 333M 26.28B | Capitalization | 3.64B 501M 39.48B |
|---|---|---|---|---|---|
| Net income 2024 * | 236M 32.5M 2.56B | Net income 2025 * | 298M 41.04M 3.23B | EV / Sales 2024 * | 1.8 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.5 x |
| P/E ratio 2024 * |
15.3
x | P/E ratio 2025 * |
12.2
x | Employees | 2,600 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.34% |
More Fundamentals
* Assessed data
More news
| 1 day | -6.48% | ||
| 1 week | -8.75% | ||
| Current month | -18.05% | ||
| 1 month | -19.25% | ||
| 3 months | -40.10% | ||
| 6 months | -59.01% | ||
| Current year | -60.50% |
1 week
27.00
29.80
1 month
27.0033.79
Current year
27.0068.99
1 year
27.0098.89
3 years
27.00408.17
5 years
27.00408.17
10 years
27.00408.17
| Managers | Title | Age | Since |
|---|---|---|---|
Chun Lin Chen
FOU | Founder | 62 | 01/02/04 |
Bin Bin Liu
DFI | Director of Finance/CFO | 47 | 31/08/16 |
Jin Na Cai
BRD | Director/Board Member | - | 30/06/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chun Lin Chen
FOU | Founder | 62 | 01/02/04 |
Jin Zhang Chen
FOU | Founder | 61 | 01/02/04 |
Zhang Qing Lin
BRD | Director/Board Member | 53 | 17/09/12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.88% | 1 M€ | -14.79% | - | |
| 0.31% | 1 M€ | -21.40% | - | |
| 0.18% | 12 M€ | -16.71% | - | |
| 0.00% | 114 M€ | +5.28% | - | |
| 0.00% | 32 M€ | +4.20% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/06/24 | 27.01 | -6.48% | 2,895,282 |
| 21/06/24 | 28.88 | +1.16% | 2,642,746 |
| 20/06/24 | 28.55 | -0.31% | 2,985,333 |
| 19/06/24 | 28.64 | -2.25% | 1,972,641 |
| 18/06/24 | 29.3 | -1.01% | 2,452,436 |
End-of-day quote Shanghai S.E., June 23, 2024
More quotes
Shanghai Medicilon Inc is a China-based company mainly engaged in pre-clinical comprehensive research and development services of biomedicine. The Company is committed to providing a full range of new drug research and development (R&D) services for pharmaceutical enterprises and other new drug R&D institutions. The Company's main businesses include drug discovery and pharmaceutical research and preclinical research. The drug discovery and pharmaceutical research mainly include services such as compound synthesis and screening, active pharmaceutical ingredients (API) and preparation technology research. The preclinical research services mainly include pharmacodynamics research, pharmacokinetics research, toxicology research and other services. The Company provides services for domestic and foreign customers such as the United States, Europe, Japan and South Korea.
Calendar
19/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
27.01
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -60.50% | 501M | |
| +16.73% | 123B | |
| +21.13% | 115B | |
| +19.83% | 25.85B | |
| -17.94% | 20.9B | |
| -16.24% | 16.52B | |
| -11.76% | 16.77B | |
| -44.45% | 15.56B | |
| +69.92% | 15.49B | |
| +1.41% | 13.45B |
- Stock Market
- Equities
- 688202 Stock
